News

Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference

Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference

Melbourne (Australia) – November 25, 2019
Telix Pharmaceuticals Limited (ASX: TLX) has today announced that Group CEO, Dr. Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe, which hosted over 500 participating companies, 2,000 attendees and 5,000 business-to-business and investor meetings.

The Jefferies 2019 London Healthcare Conference featured leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, Australia, China and Japan. Dr. Behrenbruch presented on Telix’s advanced clinical-stage portfolio of Molecularly Targeted Radiation (MTR) programs.

Dr. Behrenbruch’s presentation can be viewed at the Jefferies London Healthcare Conference website at http://www.wsw.com/webcast/jeff123/tlx/

To read the full media release click here.

More Articles

News

Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)

Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its...

News

Telix Pharmaceuticals Releases Annual Report Year Ending 2019

Melbourne (Australia) - 24 Feb 2020. Telix Pharmaceuticals Limited is pleased to provide its Annual Report for the year ending...

News

European Leadership Changes and Appointment of VP Sales and Marketing, EMEA

Melbourne (Australia) – 21st February 2020. Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her...

News

Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging

Melbourne (Australia) – 23 January 2020. Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON...

News

NDA Clinical Briefing Package Submitted to the US FDA

Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical...

News

TLX101 for Brain Cancer IPAX-1 Study Update

Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being...

News

ZIRCON Phase 3 IND Submitted to the US FDA

Melbourne (Australia) – 24 December 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Phase 3...

News

University of Melbourne collaboration with Telix receives Cancer Australia research grant

Melbourne (Australia) – 19th December 2019. Telix Pharmaceuticals Limited (ASX: TLX) is pleased to announce that Telix collaborator Professor Frédéric...

News

Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer

Melbourne (Australia) and Nantes (France) – 16, Dec 2019. Telix Pharmaceuticals Limited and French company ATONCO S.A.S today announce that...

News

Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference

Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...